Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma
De Liguori Carino, N
Hubner, Richard A
Valle, Juan W
McNamara, Mairéad G
AffiliationDepartment of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd, Manchester,
MetadataShow full item record
AbstractPancreatic ductal adenocarcinoma (PDAC) is an increasingly common cancer with a persistently poor prognosis, and only approximately 20% of patients are clearly anatomically resectable at diagnosis. Historically, a paucity of effective therapy made it inappropriate to forego the traditional gold standard of upfront surgery in favour of neoadjuvant treatment; however, modern combination chemotherapy regimens have made neoadjuvant therapy increasingly viable. As its use has expanded, the rationale for neoadjuvant therapy has evolved from one of 'downstaging' to one of early treatment of micro-metastases and selection of patients with favourable tumour biology for resection. Defining resectability in PDAC is problematic; multiple differing definitions exist. Multidisciplinary input, both in initial assessment of resectability and in supervision of multimodality therapy, is therefore advised. European and North American guidelines recommend the use of neoadjuvant chemotherapy in borderline resectable (BR)-PDAC. Similar regimens may be applied in locally advanced (LA)-PDAC with the aim of improving potential access to curative-intent resection, but appropriate patient selection is key due to significant rates of recurrence after excision of LA disease. Upfront surgery and adjuvant chemotherapy remain standard-of-care in clearly resectable PDAC, but multiple trials evaluating the use of neoadjuvant therapy in this and other localised settings are ongoing.
CitationGray, Simon, de Liguori Carino, N, Radhakrishna, Ganesh, Lamarca, Angela, Hubner, Richard A, Valle, Juan W, McNamara, Mairead G. Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. European Journal of Surgical Oncology. 2022
TypeMeetings and Proceedings
- Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
- Authors: Kaufmann B, Hartmann D, D'Haese JG, Stupakov P, Radenkovic D, Gloor B, Friess H
- Issue date: 2019
- Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
- Authors: Michelakos T, Pergolini I, Castillo CF, Honselmann KC, Cai L, Deshpande V, Wo JY, Ryan DP, Allen JN, Blaszkowsky LS, Clark JW, Murphy JE, Nipp RD, Parikh A, Qadan M, Warshaw AL, Hong TS, Lillemoe KD, Ferrone CR
- Issue date: 2019 Apr
- Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
- Authors: Heinrich S, Besselink M, Moehler M, van Laethem JL, Ducreux M, Grimminger P, Mittler J, Lang H, Lutz MP, Lesurtel M, Scientific and Research Committee of the E-AHPBA and the EORTC pancreas working group
- Issue date: 2019 Jul 9
- Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
- Authors: Choi JG, Nipp RD, Tramontano A, Ali A, Zhan T, Pandharipande P, Dowling EC, Ferrone CR, Hong TS, Schrag D, Fernandez-Del Castillo C, Ryan DP, Kong CY, Hur C
- Issue date: 2019 Jul
- Borderline resectable pancreatic cancer.
- Authors: Hackert T, Ulrich A, Büchler MW
- Issue date: 2016 Jun 1